- Business Wire•16 days agoSIGA Announces Data Safety Monitoring Board (DSMB) Approval to Complete Subject Enrollment in the Final Cohort of Phase III Study of TPOXX™ (tecovirimat)
SIGA Technologies, Inc. , a company specializing in the development and commercialization of solutions for serious unmet medical needs and biothreats, announced that it has received approval from its Data Safety Monitoring Board to complete enrollment in the second and final cohort of healthy subjects for the Phase III clinical study for its lead drug candidate, TPOXX™ , for the treatment of orthopoxvirus ...
- Capital Cube•2 months ago
Click here to see latest analysisSIGA Technologies, Inc. reports financial results for the quarter ended March 31, 2016.We analyze the earnings along side the following peers of SIGA Technologies, Inc. – Achillion Pharmaceuticals, Inc., Emergent BioSolutions Inc., SciClone Pharmaceuticals, Inc., Novavax, Inc., Sarepta Therapeutics, Inc., Sinovac Biotech Ltd., Chimerix, Inc., BioCryst Pharmaceuticals, Inc. and Newlink […] (Read more...) The post SIGA Technologies, Inc. :SIGA-US: Earnings Analysis: Q1, 2016 By the Numbers : June 28, 2016 appeared first on CapitalCube.
SIGA Technologies, Inc. (SIGA)
Other OTC - Other OTC Delayed Price. Currency in USD
|Day's Range||2.21 - 2.35|
|52wk Range||0.60 - 2.55|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-2.72|
|Avg Vol (3m)||88,714|
|Dividend & Yield||N/A (N/A)|